2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Landmesser, UlfUlfLandmesserChapman, M JohnM JohnChapmanStock, Jane KJane KStockAmarenco, PierrePierreAmarencoBelch, Jill J FJill J FBelchBorén, JanJanBorénFarnier, MichelMichelFarnierFerence, Brian ABrian AFerenceGielen, StephanStephanGielenGraham, IanIanGrahamGrobbee, Diederick EDiederick EGrobbeeHovingh, G KeesG KeesHovinghLüscher, Thomas FThomas FLüscherPiepoli, Massimo FMassimo FPiepoliRay, Kausik KKausik KRayStroes, Erik SErik SStroesWiklund, OlovOlovWiklundWindecker, StephanStephanWindeckerZamorano, Jose LuisJose LuisZamoranoPinto, FaustoFaustoPintoTokgözoglu, LaleLaleTokgözogluBax, Jeroen JJeroen JBaxCatapano, Alberico LAlberico LCatapano2024-10-252024-10-252018-04-07https://boris-portal.unibe.ch/handle/20.500.12422/155807en600 - Technology::610 - Medicine & health2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.article10.7892/boris.1074072904564410.1093/eurheartj/ehx549